Research Topics
| Patricia DanzonSummaryAffiliation: University of Pennsylvania Country: USA Publications
Research Grants
|
Detail Information
Publications
The economics of parallel tradeP M Danzon
Health Care Department, Wharton School, University of Pennsylvania, Philadelphia, USA
Pharmacoeconomics 13:293-304. 1998..This would preserve differentials in transactions prices even if parallel trade forces convergence of wholesale prices...
Drug pricing and value in oncologyPatricia M Danzon
University of Pennsylvania, Philadelphia, 19104, USA
Oncologist 15:24-31. 2010..S. data. Making such outcomes-adjusted prices available in the U.S. would be helpful to physicians, payers, and patients and indirectly constrain pricing to align with value...- International prices and availability of pharmaceuticals in 2005Patricia M Danzon
Health Care Department, Wharton School, University of Pennsylvania, Philadelphia, USA
Health Aff (Millwood) 27:221-33. 2008..Comprehensive price indexes show foreign prices to be 20-40 percent lower than U.S. manufacturer prices, but only 10-30 percent lower than U.S. public prices. Generics are cheaper in the United States than in other countries... - Prices and availability of biopharmaceuticals: an international comparisonPatricia M Danzon
Health Care Department, Wharton School at the University of Pennsylvania in Philadelphia, USA
Health Aff (Millwood) 25:1353-62. 2006..Prices for identical formulations are not higher on average in the United States. The broader price indexes, which do not control formulation, are also not higher in the United States, after adjusting for income... - Vaccine supply: a cross-national perspectivePatricia M Danzon
Wharton School, University of Pennsylvania, Philadelphia, PA, USA
Health Aff (Millwood) 24:706-17. 2005..High, country-specific, fixed costs, combined with price and volume uncertainty, plausibly deters these potential suppliers from attempting to enter the U.S. market... - Why sole-supplier vaccine markets may be here to stayPatricia Danzon
Wharton School, University of Pennsylvania, Philadelphia, PA, USA
Health Aff (Millwood) 24:694-6. 2005.... - Alternative strategies for Medicare payment of outpatient prescription drugs--Part B and beyondPatricia M Danzon
Department of Health Care Systems, The Wharton School, University of Pennsylvania, Philadelphia, PA 19104 6218, USA
Am J Manag Care 11:173-80. 2005..Folding Part B and Part D into comprehensive contracting with health plans for full health services is likely to offer the most efficient approach to managing the drug benefit... - Productivity in pharmaceutical-biotechnology R&D: the role of experience and alliancesPatricia M Danzon
University of Pennsylvania, Health Care Management Department, The Wharton School, 3641 Locust Walk, Philadelphia, PA 19104, USA
J Health Econ 24:317-39. 2005..Products developed in an alliance tend to have a higher probability of success, at least for the more complex phase 2 and phase 3 trials, and particularly if the licensee is a large firm... - Setting cost-effectiveness thresholds as a means to achieve appropriate drug prices in rich and poor countriesPatricia M Danzon
Health Care Management, Wharton School of University of Pennsylvania, Philadelphia, PA, USA
Health Aff (Millwood) 30:1529-38. 2011..Adopting this approach broadly should lead to appropriate price differences across and within countries, benefiting consumers and manufacturers alike... - Prices and availability of pharmaceuticals: evidence from nine countriesPatricia M Danzon
Wharton School s Health Care Department, University of Pennsylvania, Philadelphia, USA
Health Aff (Millwood) . 2003..K. prices in 1999 than in 1992. Our findings suggest that U.S.-foreign price differentials are roughly in line with income and smaller for drugs than for other medical services... - Closing the doughnut hole: no easy answersPatricia M Danzon
Wharton School, University of Pennsylvania, Philadelphia, USA
Health Aff (Millwood) . 2004..Careful cost-effectiveness analysis would be more appropriate than trying to import other countries' price controls. Income-related subsidies are a better strategy for dealing with excessive cost sharing for low-income seniors... - Cross-national price differences for pharmaceuticals: how large, and why?P M Danzon
Health Care Management Department, Wharton School, University of Pennsylvania, Philadelphia 19104, USA
J Health Econ 19:159-95. 2000..Strict price regulation systematically lowers prices for older molecules and globally diffused molecules. Generic competition lowers prices in less-regulated regimes, which also have more price-elastic demand... - Differential pricing for pharmaceuticals: reconciling access, R&D and patentsPatricia M Danzon
Wharton School, University of Pennsylvania, USA
Int J Health Care Finance Econ 3:183-205. 2003..Differential pricing could go a long way to improve LDC access to drugs that have a high income market. However, other subsidy mechanisms will be needed to promote R&D for drugs that have no high income market... - Reference pricing of pharmaceuticals for Medicare: evidence from Germany, The Netherlands, and New ZealandPatricia M Danzon
University of Pennsylvania, USA
Front Health Policy Res 7:1-54. 2004..S. generic market, and on research and development (R&D) and the future supply of new drugs, because of the much larger U.S. share of global pharmaceutical sales... - The economics of gene therapy and of pharmacogeneticsPatricia Danzon
Wharton School, University of Pennsylvania, Philadelphia, PA, USA
Value Health 5:5-13. 2002..This problem with small numbers is analogous to that associated with gene therapy for monogenic diseases and may require similar remedies if society values developing treatments for these diseases... - A general model of the impact of absenteeism on employers and employeesMark V Pauly
Health Care Systems Department, The Wharton School, 3641 Locust Walk, Philadelphia, PA 19104 6218, USA
Health Econ 11:221-31. 2002..In the long run, workers are likely to bear much of the incidence of the costs associated with absenteeism, and therefore be the likely beneficiaries of any reduction in absenteeism... - At what price?Patricia M Danzon
Health Care Management Department at The Wharton School, University of Pennsylvania, Philadelphia, USA
Nature 449:176-9. 2007 - The impact of price regulation on the launch delay of new drugs--evidence from twenty-five major markets in the 1990sPatricia M Danzon
Health Care Systems Department, The Wharton School, University of Pennsylvania, Philadelphia, 19104-6218, USA
Health Econ 14:269-92. 2005..Controlling for expected price and volume, country effects for the likely parallel export countries are significantly negative... - Welfare effects of supplementary insurance: a commentPatricia M Danzon
J Health Econ 21:923-6. 2002 - Effect of tiered prescription copayments on the use of preferred brand medicationsThomas S Rector
Center for Health Care Policy and Evaluation, UnitedHealth Group, Eden Prairie, Minnesota 55344, USA
Med Care 41:398-406. 2003..How much this financial incentive affects use of preferred brands has not been widely reported. The aim of this study was to estimate the effect of tiered copayments on the choice between preferred and nonpreferred brand medications...
Research Grants
- Advanced Training in Health Service ResearchPatricia Danzon; Fiscal Year: 2007....